Sanofi Closes In On A Pair Of Approval Firsts

Dupixent Approvals Expanded As Xenpozyme Gets CHMP Nod

The French major has secured a fourth approval, in eosinophilic esophagitis, for Dupixent, while the EMA is set to make Sanofi's enzyme replacement therapy, Xenpozyme, the first drug approved in Europe for acid sphingomyelinase deficiency.

Sanofi
• Source: Sanofi

Sanofi is celebrating a pair of regulatory successes for drugs that will be the first treatments to be approved for two rare diseases, acid sphingomyelinase deficiency (ASMD) and eosinophilic esophagitis (EoE).

First up is another approval in the US for the mega-blockbuster Dupixent (dupilumab) which has just received the green light...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip